There were 496 press releases posted in the last 24 hours and 150,200 in the last 365 days.

Global Matrix Protein 1 (M1 or M) Drugs and Companies Pipeline Review H1 2016

PUNE, INDIA, September 19, 2016 / -- Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016

Complete Report Details @

The, ‘Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016’, provides in depth analysis on Matrix Protein 1 (M1 or M) targeted pipeline therapeutics.

The report provides comprehensive information on the Matrix Protein 1 (M1 or M), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development and features dormant and discontinued projects.

For more information or any query mail at

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Get a Sample Report @

- The report provides a snapshot of the global therapeutic landscape for Matrix Protein 1 (M1 or M)
- The report reviews Matrix Protein 1 (M1 or M) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics and enlists all their major and minor projects
- The report assesses Matrix Protein 1 (M1 or M) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Matrix Protein 1 (M1 or M) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Matrix Protein 1 (M1 or M)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Matrix Protein 1 (M1 or M) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents – Major Key Points

Matrix Protein 1 (M1 or M) - Companies Involved in Therapeutics Development 23
Novavax, Inc. 23
Redbiotec AG 24
Sarepta Therapeutics, Inc. 25
Matrix Protein 1 (M1 or M) - Drug Profiles 26
(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
influenza (virus like particle) vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
influenza (virus like particle, tetravalent) vaccine - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
influenza [serotype A] vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
influenza [strain A/H7N9] (virus like particle, monovalent) vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
radavirsen - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
SARS (virus like particle) vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
For more information or any query mail at
Get Exclusive Discount On This Report @

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here